CTRI/2018/05/013864
Completed
Phase 2
Clinical trial on Hyperlipidemia (Kasrat-e-Shahmuddam) with UNIM-763 - KSD/H
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: I259- Chronic ischemic heart disease, unspecifiedHealth Condition 2: null- Hyperlipidemia
- Sponsor
- Central Council for Research in Unani Medicine
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Serum cholesterol: \> 200 mg/dl
- •2\.Serum Triglycerides: \>150 mg / dl
- •3\.LDL: \> 115 mg/ dl
- •4\.HDL: \> 40
- •5\.Patient should be willing to cooperate the study protocol
- •6\.Patient should be give written informed consent
- •7\.Patient should not have any other disease.
Exclusion Criteria
- •1\.Un control diabetes mellitus
- •2\.History of IHD
- •3\.History of drug/alcohol abuse
- •4\.Non cooperative patients.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Effect of Fucus homoeopathic medicine in High blood cholesterol levelsCTRI/2024/01/062141VINAYAKA MISSIONS HOMEOPATHIC MEDICAL COLLEGE AND HOSPITA
Completed
Phase 2
clinical trial to study the comparative effect of a classical unani antiobesity drug safoof-e-muhazzil on hyperlipidemia in its classical powder form and in compressed tablet formCTRI/2011/06/001825Department of Moalejat Medicine Faculty of Medicine90
Completed
Not Applicable
Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)DyslipidemiaNCT01436253Organon and Co2,196
Recruiting
Not Applicable
A Clinical study in patients with dyslipidemia to determine the actual status of the percentage of patients achieving the target values for the management of LDL-Cholesterol specified in the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases (2022 edition)JPRN-UMIN000051501TOKYO CENTER CLINIC180
Completed
Not Applicable
A Clinical study in patients with dyslipidemia to determine the status of recognition and the percentage of patients achieving the target values for the management of each lipid parameter specified in the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases (2022 edition), and to follow-up the achievement of the target values by subsequent treatment approaches.DyslipidemiaJPRN-UMIN000046687Medical Corporation Chiseikai Tokyo Center Clinic350